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Mass drug administration against malaria and parasitic worm co-infections is capable of
increasing health risk. This study investigated the hepatotoxicity, genotoxicity and
oxidative stress induced by combinations of Arthemether-Lumefantrine (A-L) with
Albendazole (ABZ) and Ivermectin (IVR) treatments in rats. 65 rats equally distributed
into 13 groups were orally gavaged human therapeutic doses (1.0), half of the doses
(0.5) and twice the doses (2.0) of these drugs per body weights. Blood, liver and bone
marrow cells were analyzed for serum biochemistry, histopathology and micronucleated
polychromatic erythrocytes (MNPCE) respectively. Treated rats showed clinical signs of
toxicity. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bili-
rubin and malondialdehyde (MDA) significantly increase with concomitant decrease in
superoxide dismutase (SOD) and catalase (CAT) in the serum. Liver histology revealed
single cell hepatocellular necrosis and kupffer cell hyperplasia, multiple foci vacuolar
changes in the hepatocytes, thinning of hepatic cord and congestion of the sinusoids by
inflammatory cells. Also, frequency of MNPCE significantly increased in the treated rats.
The findings revealed that combine treatment of A-L with ABZ and IVR mostly at 2.0
and 1.0 induced liver dysfunctions and somatic mutations through oxidative stress in
rats. These suggest health risk in wildlife and human populations during treatments
with these drug combinations.
Copyright 2015, Mansoura University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).415.
hivoptera@yahoo.com (C.G. Alimba).
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Parasites infect more than 200 million people worldwide.
Chronic infestations may elicit inflammation, lead to cancer
formation and deaths [1]. Infections from parasitic worms and
protozoa are themajor cause of human andwildlifemorbidity
andmortality. In tropical and sub-tropical regions, Plasmodium
species, the parasitic protozoan responsible for human and
animal malaria, is the leading cause of morbidity and mor-
tality with children highly vulnerable, accounting for about
1e2 million deaths annually [2]. Similarly, schistosomiasis,
lymphatic filariasis, ascariasis, enterobiasis and onchocerci-
asis caused by helminthes and nematodes, are common
health issues inmost tropical and sub-tropical countries [3]. In
endemic situations, these protozoan and worms coexist in
human and animals to cause severe infestation and death [4].
In this situation, mass drug administration is usually the
recommended treatment strategy for effective parasite
clearance [5].
Coartem®, an artemisinin combination therapy containing
Artemether-Lumefantrine (A-L), is the leading and first line
drug recommended for the treatment of acute and compli-
cated malarial fever in patients with minimum 5 kg body
weight [6e8]. Clinical trials showed that Coartem® is effective,
safe and has good tolerability against multi-drug resistant
Plasmodium falciparum [9,10]. It produces about 10,000 folds
decrease in parasite biomass per asexual cycle [11]. Albenda-
zole (ABZ) and Ivermectin (IVR) are effective anti-parasitic
agents usually recommended for the treatment of human
and veterinary parasitic worm infections [12e14]. Co-
administration of these drugs with A-L during helminthic,
nematode and malarial co-infection or resistance has shown
to be effective. Horton et al. [15] reported that single dose of
IVR and ABZ combined therapy against lymphatic filariasis
produced better treatment efficacy than the individual drug
effects. Mohammed et al. [16] also reported that co-
administration of praziquantel and ABZ was effective
against schistosomiasis and soil-transmitted helminthiasis
morbidity. A-L a fixed-dose combination tablet of 20 mg
artemether and 120 mg lumefantrine in the ratio 1:6 is effec-
tive against complicated P. falciparum malaria [8,17]. These
reports are in support of the efficacy of mass drug adminis-
tration against co-infections caused by parasitic protozoa and
worms.
Considering that drugs are synthetic chemicals, they are
capable of producing both beneficial and harmful effects. It is
important to evaluate the possible deleterious effects of
administering mass drugs during protozoa and worm co-
infections to avert the probable health effects. This is neces-
sary considering that the harmful drug effects have been
linked to liver damage, bone marrow toxicity, carcinogenesis
and fetal developmental anomalies [18,19]. It is plausible that
combine drug administration against malaria and parasitic
worm co-infection may elicit toxic effects in the host due to
drugedrug interactions [20]. In vivo and in vitro studies of in-
dividual drugs; A-L, ABZ and IVR induced various toxicities in
biological systems. Artemether treatment induced necrosis in
gastric cancer cell line (PG100), and necrosis and apoptosis in
human lymphocytes [24]. ABZ induced cytotoxicity in livercells of treated rats via elevation of liver function enzymes
and alterations in oxidative stress enzymes during sub-
chronic exposure [25]. IVR similarly induce cytotoxicity and
genotoxicity in treated mice and Chinese hamster ovary cells
[20,26]. These reports showed that A-L, ABZ and IVR are
potentially harmful to biological systems. They may be
considered effective and safe at therapeutic doses, but an
overdose may result into severe tissue injury, organ failure
and death [27].
Liver, the most sensitive predictor of chemical induced
toxicity due to its involvement in metabolism, detoxification
and storage of drugs and their metabolites, is an important
target organ for drug induced injury in mammals [25,28,29].
Also, bone marrow the site of blood cell proliferation may be
subject to drug induced toxicity during acute and chronic
exposure [25,26]. Considering that Artemether and Lumefan-
trine (A-L), Ivermectin (IVR) and Albendazole (ABZ) may be
ignorantly abused following the mass drug administration
strategy in the control of malaria and parasitic worm co-
infection. It is important to understand the possible mecha-
nism of liver dysfunctions and bone marrow cell toxicity
(genotoxicity) of combine treatments of A-L, IVR and ABZ in
mammalian systems is linked to reactive oxygen species
formation.
This study investigated the hepatotoxicity, genotoxicity
(using micronucleus assay) and alterations in serum antioxi-
dant enzymes (catalase and superoxide dismutase) and lipid
peroxidation as possible mechanisms of co-administrations
of A-L, ABZ and IVR induced toxicity in Wistar rats.2. Materials and methods
2.1. Chemicals
Artemisinin-based combination therapy containing Arte-
mether and Lumefantrine (A-L); Coartem® (Norvatis Pharma-
ceuticals Corporation Suffern, New York, USA), Ivermectin
(IVR); Mectizan® (Merck & Co., Inc., Whitehouse station, New
Jersey, USA) and Albendazole (ALB); Expezol® (Swiss Pharma
Nigeria Limited, Lagos), Cyclophosphamide monohydrate
(Endoxan™ Mfg Lic. No. 186. Frankfurt am Main, Germany),
positive control, Fetal calf serum (Sigma St Louis, MO, USA),
Giemsa and May-Gru¨nwald stains (Merck, Germany) used for
this study were of analytical grades.2.2. Animals
Sixty five (65) male Wistar rats (between 7 and 8 weeks old)
obtained from the animal unit, College of Medicine, University
of Ibadan, Nigeria were used for the study. They were accli-
matized for 14 days until they were 134.0 ± 2.0 g (mean ± SD)
body weight. They were maintained in laboratory conditions
of 12 h dark and light cycle, temperature of 27 ± 8 C, relative
humidity of 69 ± 15% and had access to clean drinking water
and standard rodent chow (Ladokun feed Nigeria®) ad libitum.
Guide for care and use of Laboratory Animals published by US
National Institutes of Health (NIH Publication No. 85e23,
revised in 1996), and approved by the ethical committee,
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studies was carefully adhered.2.3. Experimental design and drug administration
5 rats per group were randomly distributed into 13 experi-
mental groups with cyclophosphamide (CYP, 20 mg/kg/bwt)
and distilled water (vehicular solvent) used as positive and
negative controls respectively. Human therapeutic doses for
the three drugs (1.0), sub-curative (half of the dose;0.5) and
twice the doses (2.0) were administered to the rats via oral
gavaging according to their body weights (mg/kg). The
experimental groups are A (negative control), B [human
therapeutic dose for Artemether-Lumefantrine, 20/120 mg/kg
bwt (1.0 AL)] [7,10], C [sub-curative human therapeutic dose
for Artemether-Lumefantrine, 10/60 mg/kg bwt (0.5 AL)], D
[twice the human therapeutic dose for Artemether-
Lumefantrine, 40/240 mg/kg bwt (2.0 AL)], E [human thera-
peutic doses for Artemether-Lumefantrine, 20/120 mg/bwt
and Albendazole, 400 mg/kg bwt (1.0 AL þ ABZ)] [39], F [sub-
curative human therapeutic doses for Artemether-
Lumefantrine, 10/60 mg/bwt and Albendazole, 200 mg/kg;
(0.5 AL þ ABZ)], G [(twice of the therapeutic doses
Artemether-Lumefantrine, 40/240 mg/bwt and Albendazole,
800 mg/kg (2.0 AL þ ABZ)], H [human therapeutic doses for
Artemether-Lumefantrine, 20/120 mg/bwt and Ivermectin,
3 mg/kg (1.0 AL þ AVR)] [13,41], I [sub-curative therapeuticTable 1e Experimental animal grouping and drug dosage
and administration.
Experimental
groups
Drug doses
(mg/kg bwt)
Exposure durations
A Distilled water 0.5 ml for 3 consecutive
days
B 20/120 AL 0.5 ml for 3 consecutive
days
C 10/60 AL 0.5 ml for 3 consecutive
days
D 40/240 AL 0.5 ml for 3 consecutive
days
E 20/120 AL þ 400
ABZ
0.5 ml AL þ 0.5 ml ABZ for
3 days
F 10/60 AL þ 200
ABZ
0.5 ml AL þ 0.5 ml ABZ for
3 days
G 40/240 AL þ 800
ABZ
0.5 ml AL þ 0.5 ml ABZ for
3 days
H 20/120 AL þ 3 IVR 0.5 ml AL þ 0.5 ml IVR for
3 days
I 10/60 AL þ 1.5 IVR 0.5 ml AL þ 0.5 ml IVR for
3 days
J 40/240 AL þ 6 IVR 0.5 ml AL þ 0.5 ml IVR for
3 days
K 20/120 AL þ 400
ABZ
0.5 ml AL for 3days þ 0.5 ml
ABZ only on the 3rd day
L 20/120 AL þ 3 IVR 0.5 ml AL for 3days þ 0.5 ml
ABZ only on the 3rd day
M 40 CYP 0.5 ml for 3 consecutive days
AL ¼ Artemether-Lumefantrine (Artemisinin-based combination
therapy; Coartem®); IVR¼ Ivermectin; ABZ ¼ Albendazole;
CYP¼Cyclophosphamide (positive control). Drugs were consti-
tuted using distilled water (vehicular solvent; negative control).doses for Artemether-Lumefantrine, 10/60 mg/bwt and Iver-
mectin, 1.5 mg/kg (0.5 AL þ IVR)], J [twice of therapeutic
doses for Artemether-Lumefantrine, 40/240 mg/bwt and
Ivermectin, 6 mg/kg (2.0 AL þ IVR)], K [therapeutic doses for
Artemether-Lumefantrine, 20/120 mg/bwt and single admin-
istration of Albendazole, 400 mg/kg], L [therapeutic dose for
Artemether-Lumefantrine, 20/120 mg/bwt and single admin-
istration of Ivermectin, 3 mg/kg] and M [Cyclophosphamide,
(CYP) 20 mg/kg]. The drugs were administered to the various
groups for three consecutive days. Similar treatment was
concurrently given to the negative control group, A (distilled
water; vehicular solvent). Table 1 presents the summary of the
experimental design for drug administration to the various
groups.2.4. Clinical signs of toxicity and mortality
Rats in each treatment group were observed twice daily
(before and after exposure) for signs of clinical toxicity in the
appearances of their skin and fur, eyes and mucous mem-
brane, behavioral pattern, morbidity and mortality.2.5. Serum biochemical analysis
At the end of exposure periods, rats were fasted overnight and
blood collected from the orbital plexus using heparinized
70 ml micro-hematocrit capillary tubes into lithium coated
serum separator tubes. The clotted blood was centrifuged at
3000 g for 10 min to separate the serum (supernatant) and
stored at 70 C prior to biochemical analysis. Serum
biochemical markers of oxidative stress were measured ac-
cording to standard protocols: Catalase (CAT; EC 1.11.1.6) ac-
tivity was measured according to the method of Aebi [30],
superoxide dismutase (SOD; EC 1.15.1.1) activity was
measured in accordance with Magwere et al. [31] method,
while lipid peroxidation was measured as malondialdehyde
(MDA) concentrations in accordance with Nichaus and
Samuelson [32] method. Protein concentration was measured
according to the methods of Lowry et al. [33]. Serum liver
function test markers; transaminases were measured ac-
cording to Reitman and Frankel [34] and total bilirubin ac-
cording to Treitz [35] using Randox Laboratory (UK) diagnostic
kits. The absorbances for all the reactions were measured
spectrophotometrically using HAICE®, DR 3000 (Germany).2.6. Mammalian bone marrow micronucleus assay
Bone marrow micronucleus test was conducted according to
Schmid [36]. Femoral bones from treated and control rats were
surgically removed and the bone marrow flushed into
eppendof tubes using 0.5 ml of Fetal Bovine Serum (FBS). The
cells were centrifuged at 2000 rpm for 5 min and smear made
on pre-cleaned grease free slides. Prepared slides were air
dried and stained with May-Grunwald and Giemsa stains.
They were coded and examined under an Olympus light mi-
croscope at 1000 magnification. 2000 cells per rat were
scored for micronucleated polychromatic erythrocytes
(MNPCE).
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Slices of the right lobe of the liver tissue from drug treated
and control rats were fixed in 10% neutral buffered formalin.
The tissues were dehydrated in ascending order of ethyl
alcohol-water concentrations, cleared in xylene and
sequentially embedded in paraffin wax blocks using rotary
microtome. Tissue sections of 3e5 mm thick were cut and
prepared on clean slides for Hematoxylin-Eosin (H-E)
staining before mounting in neutral DPX medium. Prepared
slides were examined at 400 magnification by trained
pathologist.
2.8. Statistical analysis
All statistical analyses were conducted with Graphpad prism
5.0® computer programs. One-way ANOVA was used to
determine the differences (p < 0.05) among the various
treated groups and control. Difference between each treat-
ment group and the negative control was determined using
comparison procedure of the Dunnett multiple post-hoc test
(DMPT). Significance was considered at p < 0.05; p < 0.01 and
p < 0.001.Fig. 1 e Abscess on the thigh region of the right leg of rat
exposed to Artemether/Lumefantrine (20/120 mg/bwt) and
Ivermetin (3 mg/kg), sign of clinical toxicity to drug
exposure.3. Results
3.1. Clinical signs of toxicity and mortality
During the exposure periods, two animals died, one each in
groups E and G. The survivors in groups D, E, G, H, J, K and L
exhibited sluggishness and weakmovement (signs of reduced
activities), diarrheae, ungroomed fur and labored breathing
movement. They also exhibited reduction in their feeding
habit. A rat in the H group developed abscess in the thigh re-
gion of the right leg (Fig. 1). These signs of toxicity were rarely
observed in rats from groups B, C, F and I and none was
observed in the negative control group. There was no signifi-
cant change in the body weight gain and liver weight gain
between treatment groups and the negative control (data not
shown).
3.2. Biochemical indicators of hepatic function, lipid
peroxidation and oxidative stress
Fig. 2(aec) presents the results of the serum hepatic function
tests. The activities of ALT, AST and total bilirubin concen-
tration significantly (p < 0.001) increased in rats exposed to the
drug combinations. Drug exposure to rats in groups D, E, G, H,
J, K and L resulted in significant increase in ALT activity by
37.69, 38.52, 78.13, 58.72, 94.65, 50.66 and 71.94% folds
respectively aswell as AST activity by 26.05, 34.74, 98.51, 67.29,
127.77, 66.42 and 81.41% folds respectively compared to the
negative control. Table 2 shows the results of the antioxidant
enzyme activities and lipid peroxidation. SOD and CAT ac-
tivities significantly (p < 0.05) decreased in the drug adminis-
tered groups compared to the negative control, with the
reduction dependent on drug treatment groups. The per-
centage decrease for SOD activities in rats from E, G, H, L, K,
and J groups were significantly different from the negativecontrol by 33.33, 40.33, 21.28, 18.41, 15.08 and 29.11% folds
respectively. While the percentage decrease for CAT activity
in rats from E, G, H, L, K and M groups are 31.82, 47.98, 22.22,
7.07, 17.68 and 31.31% folds respectively. Reduction in the
activities of these enzymes is accompanied with concomitant
significant (p < 0.05) increase in MDA concentration with
34.78, 73.46, 2.13, 11.0, 14.11 and 48.36% folds increase for rats
in the treatment groups: E, G, H, L, K and J respectively
compared to the negative control. The results of the
biochemical alterations showed positive correlations accord-
ing to the drug administration (Fig. 2aec and Table 2).
3.3. Micronucleus analysis
Fig. 3 shows the genotoxicity data. There is significant in-
crease (p < 0.05) in the frequencies of micronucleated poly-
chromatic erythrocytes. The treatment groups: E, G, H, J, K and
L were significantly higher than the negative control by 6.78,
8.12, 1.81, 3.11, 5.49 and 2.97 folds respectively. Fig. 4 shows
representative polychromatic erythrocyte (PCE) and micro-
nucleated PCE scored for the genotoxicity assessment of the
drugs.
3.4. Histopathological assessment of the liver
Fig. 4aef presents the histological sections of the liver from
the treated rats and the negative control. Sections of the
liver from the negative control rats showed apparently
normal hexagonal or pentagonal lobule of the hepatocytes.
These cells are regular and contain a large spheroidal nu-
cleus (Fig. 4a). Histology of the liver tissues from combined
drug treated rats showed some distorted architectural
structures from the negative control. These alterations are
single cell hepatocellular necrosis and kupffer cell hyper-
plasia, which were common among most treated rats in the
following groups; D, E, G, H, J, K, L and the positive control.
Also multiple foci vacuolar changes in the hepatocytes,
thinning of hepatic cord and congestion of the sinusoids by
inflammatory cells were observed in these treated groups
(Fig. 5bef).
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Fig. 2 e a. Effects of drug exposure on serum ALT activity of rat. End point represents mean ± SE for 5 rats. Values are
significantly different; ap< 0.05; bp < 0.01; cp < 0.001 and *p > 0.05 compared to negative control. b. Effects of drug exposure
on serumAST activity of rat. End point represents mean ± SE for 5 rats. Values are significantly different; ap< 0.05; bp < 0.01;
cp < 0.001 and *p > 0.05 compared to negative control. c. Effects of drug exposure on total bilirubin concentration of rat. End
point represents mean ± SE for 5 rats. Values are significantly different; ap< 0.05; bp < 0.01; cp < 0.001 and *p > 0.05
compared to negative control.
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Mass drug administration strategy against protozoa and
worm co-infections [8] is capable of increasing human expo-
sure to multiple drug combinations. Mostly in developing
countries where drugs are readily purchased from unregis-
tered patent medicinal stores and hawkers without physicianTable 2 e Effects of drug combinations on serum CAT, SOD an
Treatment SOD (95% CI) CAT
A 31.29 ± 2.43 (27.32e35.26) 1.98 ± 0
B 29.73 ± 1.68* (27.49e31.98) 1.86 ± 0
C 29.72 ± 3.49* (25.57e33.87) 1.94 ± 0
D 23.63 ± 3.32b (19.96e27.30) 1.75 ± 0
E 22.86 ± 0.93c (18.18e23.53) 1.35 ± 0
F 26.56 ± 0.95a (21.16e31.97) 1.66 ± 0
G 20.65 ± 2.02c (17.81e23.48) 1.03 ± 0
H 24.63 ± 1.45a (23.59e31.67) 1.54 ± 0
I 30.43 ± 0.68* (25.76e35.10) 1.75 ± 0
J 22.18 ± 1.61b (17.75e26.88) 1.36 ± 0
K 26.57 ± 1.71a (21.77e31.28) 1.63 ± 0
L 25.53 ± 1.16a (24.31e30.75) 1.84 ± 0
M 25.48 ± 2.36a (21.70e29.25) 1.42 ± 0
End point represents mean ± SE for 5 rats. Values are significantly differe
control. SOD (superoxide dismutase; U/mg protein), CAT (catalase; mmo
interval).prescriptions. Free access to drugs, coupled with wrong
application due to ignorance of drug toxicity may endanger
human and animal health. Ivermectin, Albendazole and
Artemether-Lumefantrine used in this study were selected
based on their overwhelmingly and extensively use as broad-
spectrum anti-nematode, anti-helminthic and antimalarial
drugs respectively [5,7,13,14,37]. Also individual toxic effectsd MDA in treated and control rats.
(95% CI) MDA (95% CI)
.02 (1.36e2.60) 28.64 ± 1.16 (25.42e31.86)
.13* (1.22e2.49) 32.72 ± 2.82* (27.66e37.77)
.09* (1.41e2.48) 29.62 ± 1.66* (25.01e34.23)
.17* (1.28e2.22) 41.80 ± 0.96c (36.37e35.88)
.21a (1.04e1.66) 38.60 ± 0.93b (33.24e43.95)
.01a (1.36e1.95) 40.41 ± 1.49c (33.50e47.31)
.08b (0.26e1.80) 49.68 ± 2.00c (44.14e55.22)
.16a (1.09e1.99) 29.25 ± 3.08* (26.26e32.24)
.26* (1.30e2.20) 30.67 ± 1.13* (24.75e36.59)
.01a (1.04e1.68) 42.49 ± 0.38c (35.88e49.10)
.20a (1.07e2.19) 32.68 ± 2.74a (27.86e33.24)
.03* (1.47e2.21) 31.79 ± 1.53* (27.54e36.04)
.13a (1.06e1.79) 35.72 ± 3.03a (30.09e41.34)
nt; ap < 0.05; bp < 0.01; cp < 0.001 and *p > 0.05 compared to negative
l/mg protein), MDA (malondialdehyde; nmol/ml), (95% confidential
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Fig. 3 e Frequency of micronucleated polychromatic
erythrocytes in bone marrow cells of rats exposed to drugs
and controls. End point represents mean ± SE for 5 rats.
Values are significantly different; ap< 0.05; bp < 0.01;
cp < 0.001 and *p > 0.05 compared to negative control.
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[21e23,25,27,38,39], but there is dearth of information on the
toxic effects of their binary combinations. This study corrob-
orated oxidative stress induced by binary combinations of AL,
AL þ ABZ and AL þ IVR with structural and biochemical al-
terations in the liver, and micronuclei polychromatic eryth-
rocyte formation in the bone marrow cells of rats.
Clinical signs of toxicity observed in the treated rats in
groups D, E, G, H, J, K and L suggest systemic toxicity of the
drug combinations in the treated rats. Anorexia (loss of
appetite) is a common symptom of liver injury attributable to
drug exposure and is consistent with reduced activities;
sluggishness andweakness [40]. Labored breathing, diarrheae,
ungroomed hair and hair loss observed in the treated rats are
common symptoms of hepatotoxicity and immune systems
dysfunction due to toxicosis from overdose of the adminis-
tered drugs and their pharmacokinetics [41,42]. Mortality
recorded at the 1.0 AL þ ABZ (group E) and 2.0 AL þ ABZ
(group G) treatment may be associated with overdose which
caused acute toxicity. Abscess observed in a rat from group H
(1.0 AL þ IVR) may be associated with cellular inflammatory
actions induced by the drug combination. This assertion lendsFig. 4 e (aeb): Asterisks showed normal polychromatic erythro
erythrocytes from bone marrow cells of rats.credence to the observed necrotic cells in the liver of the 1.0
AL þ IVR treated rats. Moreover, high dose administration of
Ivermectin induced neutrophilic activation and eosinophilic
bursting of the human peripheral blood [43,44] further sup-
ported the cellular inflammatory actions of the drugs.
Generally inflammatory cells; macrophages, neutrophils and
lymphocytes function by destroying invading microorgan-
isms, removal of necrotic cells (accidental cell death) and
cellular debris caused by drugs and other xenobiotics during
phagocytosis [45,46]. This process is usually associated with
intracellular ROS formation via autoxidation [45], which is in
support of Hyslop et al. [47] that abscess is associated with
inflammatory processes capable of producing ~100 mMof H2O2
(ROS). Alterations in the anti-oxidant enzymes and lipid per-
oxidation status of the treated rats compared to the negative
control further supported the cellular inflammatory actions.
The liver in mammalian systems is prone to drug-induced
injury due to its central role in drug metabolism, detoxifica-
tion, storage, and portal location within the circulation [48]. It
is the most sensitive predictor of chemical toxicity that cor-
relates well with histopathology and serumbiochemistry with
little inter-animal variations [19]. As the major site of AL, ABZ
and IVR metabolism [25,49,50], the liver may be prone to the
toxic effects of these drugs and or their metabolites. Cell
membrane damage in the liver is usually associated with the
release of a number of cytoplasmic enzymes into the circu-
latory system; this provides the basis for clinical diagnosis.
SerumAST and ALT are themost used biochemicalmarkers of
hepatocellular necrosis and are considered sensitive in-
dicators of hepatic drug induced injuries [51,52]. Significant
increase in the activities of serumALT, AST and total bilirubin
observed in the treated rats mostly from groups D, E, G, H, J, K
and L suggests acute hepatocellular injury due to drug induced
necrosis. It is suggested that the administered drugs and or
their metabolites induced lipid peroxidative damage to the
hepatocytes (accidental cell death; necrosis) which increased
cell membrane permeability to the cellular enzymes. This is
supported by the observation of numerous hepatic necroses in
the liver cells and significant increase in serum lipid peroxi-
dation in the treated rats. Moreover the reports that Iver-
mectin [29], Abendanzole [25], Artemether-Lumefantrine [49]
and co-administration of albendazole and ivermectin [50]
treated rats at different concentrations significantlycytes while arrows showed micronucleated polychromatic
Fig. 5 e Liver tissues of rats exposed to drug combinations (H&E, x 400). (a) Section of liver from rat in the negative control
group showing relatively normal hexagonal or pentagonal lobule of hepatocytes. (b) Single cell hepatocellular necrosis and
kupffer cell hyperplasia (c) Multiple foci vacuolar changes and congestion of the sinusoids. (d) Thinning of hepatic cord and
single cell hepatocellar necrosis. (e) Vacuolar changes in the hepatocytes and mild congestion of the sinusoids. (f) Severe
congestion of the sinusoids by inflammatory cells.
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observations herein. Also, increase in serum total bilirubin
concentration with concomitant elevation of transaminases
in AL treated rats have been associated with hepatocellular
injury [53,54]. Histological study yields the most reliable in-
formation on the type of lesions induced by drugs and their
metabolites in tissues. It is also useful in providing informa-
tion about acute and chronic effects of toxic substances that
may not be detected by biochemical analysis [55,56]. Acute
exposure of the drug combinations induced hepatic necrosis,
kupffer cell hyperplasia and congestions of the hepatocytes by
inflammatory cells observed in the liver cells of the treated
rats correlated with the clinical signs and biochemical find-
ings. These lesions were similarly reported in rats dosed with
combination of Artemether-Lumefantrine and were attrib-
uted to drug induced liver injury [57].
Drug combinations can act in synergy, potentiation and or
antagonism to induce alterations in enzyme biochemistry,
biological molecules (ROS) and cell membrane [20,58,59].
These alterations may include increase in cellular formation
of oxidative stress via creating imbalance between ROS and
the antioxidant systems [48]. SOD activity is important in
preventing oxidative damage by scavenging and converting
superoxide anions to hydrogen peroxides, while catalase
causes the decomposition of the hydrogen peroxide to protect
tissues from the actions of the highly reactive hydroxyl radi-
cals [52,60]. During these processes the activities of these en-
zymes may be altered leading to ROS induced pathological
disorders and DNA damage [46]. The observed significant
decrease in the activities of SOD and CAT in the treated rats
suggests harmful effects of the drug combinations (groups D,
E, G, H, J, K and L) via excess undetoxified free radical forma-
tion. These unscavenged free radicals probably induced lip-
operoxide formation which caused lipid peroxidation in the
cell membrane (increase MDA concentration) of the treatedrats. Studies using rats exposed to AL [49,53] and ABZ [61], and
rabbits treated with IVR [62,63] showed reduced SOD and CAT
activities either in the serum or liver with concomitant in-
crease inMDA concentrations, are in concert with the findings
herein.
Micronucleus (MN) test is the most widely utilized and
recommended test for the genotoxic and mutagenic evalua-
tion of chemicals [64,65]. This is due to its technical simplicity
and ability to detect both clastogens and aneugens [64]. The
significant increase in the MNPCE observed in bonemarrow of
rats treated with 2.0 AL, AL þ ABZ, 2.0 AL þ ABZ, AL þ IVR,
2.0 AL þ IVR in groups D, E, G, H and J respectively suggests
DNA damage induced by the tested drug combinations. It is
plausible that the drug combinations induced MNPCE was via
ROS formation. Since DNA damage may be associated with
accidental cell death (necrosis) or apoptosis induced by reac-
tive oxygen species [66]. The combination of these drugs
possibly affected the actively proliferative bone marrow cells
during the M-phase of the cell cycle to induce oxidative DNA
damage in the treated rats. Similar data obtained from the
cyclophosphamide treated rats (positive control; groupM) is in
support of this assertion. Cyclophosphamide, an alkylating
agent widely used in cancer chemotherapy [67], is known to
alkylate DNA and protein via oxidative stress induction
[68,69], leading to cytotoxicity and genotoxicity [68]. Alter-
ations in the serum oxidative stress parameters and increase
MNPCE formation in the bone marrow of cyclophosphamide
treated rats (positive control; group M), validated the findings
herein. Studies similarly reported that mice treated with
abendazole harbored significant increase MNPCE in the bone
marrow [70]. Pediatric patients with hepatic hydatid disease
on abendazole treatment presented significant increase in
sister chromatid exchange (SCE) and micronucleus fre-
quencies in peripheral lymphocytes [39]. Also, mice exposed
to ivermectin expressed higher chromosome aberration,
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negative control [20]. The combinations of the tested drugs
generated reactive oxygen species (ROS) which played
important role in MNPCE formation in the treated rats. So-
matic DNA damage due to drug toxicity predisposes cells to
chromosome related disorders, aging and carcinogenicity
[29,39,59,71,72].
The role of oxidative stress in the induction of abnormal
cellular functions and pathological disorders are the current
research focus for many studies [73e75]. Oxidative stress
induced cell damage may occur via a number of mecha-
nisms [74] and the damaged cells may be eliminated either
by programmed cell death (apoptosis) or accidental cell
death (necrosis). Necrosis, the most common histological
lesions observed in the liver of the treated rats, is associated
with the destruction of certain signal pathways in the
cells and the disruption of mitochondrial functions via in-
flammatory process [76]. Cellular necrosis and inflammatory
cells have been associated with liver damage in Artemether-
Lumefantrine treated rats [57]. This study showed that the
combination of the tested drugs, mostly at higher
doses elicited ROS formation in rats. Oxidative stress in-
duction correlated with cellular necrosis, inflammatory cell
production and other pathological lesions observed in the
hepatocytes. Also MNPCE formation in bone marrow cells
of rats. In conclusion, A þ L, AL þ ABZ, and AL þ IVR
drug combinations induced hepatotoxicity and somatic
mutation in rats may be associated with oxidative stress
induction.
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